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Abstract
Sorsby fundus dystrophy (SFD) is a macular degeneration caused by mutations in TIMP3, the
majority of which introduce a novel cysteine. However, the exact molecular mechanisms under-
lying SFD remain unknown.We aimed to provide novel insights into the functional consequences
of a distinct N-terminal mutation. Haplotype reconstruction in three SFD families revealed that
the identified c.113C>G, p.(Ser38Cys) mutation is a founder in Belgian and northern French
families with a late-onset SFD phenotype. Functional consequences of the p.(Ser38Cys) muta-
tion were investigated by high-resolution Western blot analysis of wild type and mutant TIMP3
using patient fibroblasts and in vitro generated proteins, and bymolecular modeling of TIMP3 and
its interaction partners. We could not confirm a previous hypothesis on dimerization of mutant
TIMP3 proteins. However, we identified aberrant intramolecular disulfide bonding. Our data pro-
vide evidence for disruption of the established Cys36-Cys143 disulfide bond and formation of a
novel Cys36-Cys38 bond, possibly associated with increased glycosylation of the protein. In con-
clusion, we propose a novel pathogeneticmechanism underlying the p.(Ser38Cys) TIMP3 founder
mutation involving intramolecular disulfide bonding. These results provide new insights into the
pathogenesis of SFD and other retinopathies linked to mutations in TIMP3, such as age-related
macular degeneration.
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1 INTRODUCTION
Sorsby fundus dystrophy (SFD; MIM# 136900) is a rare, autosomal
dominant retinal dystrophy in which patients experience a sudden loss
of central vision related to the development of choroidal neovascu-
larization (CNV) or macular atrophy during the fourth or fifth decade
of life (Sorsby, Joll Mason, & Gardener, 1949). The disease is char-
acterized by thickening of the Bruch membrane, chorioretinal atro-
phy, and multiple drusen-like deposits throughout the entire fundus.
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These deposits are very similar to findings in early age-related mac-
ular degeneration (AMD; MIM# 603075) (Gourier & Chong, 2015),
however the diffuse Bruch membrane thickening observed in SFD
is not limited to the macula as in AMD. Typical manifestations
include night blindness, scotoma, and metamorphopsia with subse-
quent reduced central, detailed vision and color vision problems
(Christensen, Brown, Cree, Ratnayaka, & Lotery, 2017). In the more
advanced stages, peripheral vision is lost with the development of
widespread atrophy, with any remaining function hampered by periph-
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eral CNV and scarring (Felbor et al., 1997; Gliem et al., 2015). Man-
agement of CNV in the later stages of the disease can be successful
using vascular endothelial growth factor (VEGF)-inhibitors (Gourier &
Chong, 2015). SFD is a fully penetrant disease with large interfamilial
and intrafamilial variability in age of onset, progression rate, and mor-
phological features (Christensen et al., 2017; Gliem et al., 2015).
SFD is caused by mutations in TIMP3 (MIM# 188826), which is a
member of the family of tissue inhibitor of matrix metalloproteinases
(TIMPs). TIMPs are key regulators of the matrix metalloproteinases
(MMPs), zinc-dependent endopeptidases that degrade the extracel-
lular matrix (ECM) and shed cell surface molecules (Brew & Nagase,
2010; Clark, Swingler, Sampieri, & Edwards, 2008). TIMP3 is unique
among its family members as it is the only TIMP localized to the
ECM (Qi & Anand-Apte, 2015; Visse & Nagase, 2003). The protein is
secreted by the retinal pigment epithelium (RPE) and deposited in the
ECM of the Bruch membrane, where it regulates the thickness of the
Bruch membrane by inhibiting MMPs (Weber, Vogt, Pruett, Stöhr, &
Felbor, 1994). Mutations in TIMP3 result in an increased accumulation
of the TIMP3 protein and a thickening of Bruch membrane, leading to
reduced permeability for trafficking metabolites and nutrients (Kamei
& Hollyfield, 1999). However, the exact molecular mechanisms under-
lying SFD remain unknown.
Each TIMP contains an N- and C-terminal domain, which fold into
a highly conserved tertiary structure. The N-terminal domain forms a
ridge that fits into the active site of the MMPs, thus inhibiting these
MMPs (Li, Clarke, Barker, & McKie, 2005; Nagase, Visse, & Murphy,
2006), whereas the C-terminal domain ascertains the interaction with
the ECM and inhibits activation of pro-MMPs (Brew & Nagase, 2010;
Nagase et al., 2006). The three-lobed structure of each domain is
maintained by three disulfide bonds, formed by 12 conserved cysteine
residues in total (Li et al., 2005; Nagase et al., 2006). To date, 18
distinct mutations causing SFD have been identified (Christensen
et al., 2017), the majority of which are missense mutations located
in the C-terminal domain of the protein (Bakall, Sohn, Riley, Brack, &
Stone, 2014; Schoenberger & Agarwal, 2013). One mutation causes
the loss of a cysteine, whereas 13 mutations result in an additional
cysteine residue (Gliem et al., 2015). Most studies hypothesize that
mutant TIMP3 proteins with unpaired cysteines form abnormal
disulfide-bonded dimers and aggregates that decrease the turnover
of the protein in the Bruch membrane, thus leading to a disturbed
homeostasis in ECM remodeling and thickening of Bruch membrane
(Arris et al., 2003; Langton, Barker, & McKie, 1998; Langton, McKie,
Smith, Brown, & Barker, 2005; Langton et al., 2000; Lin, Blumenkranz,
Binkley, Wu, & Vollrath, 2006; Saihan et al., 2009; Soboleva, Geis,
Schrewe, & Weber, 2003; Weber et al., 2002; Yeow et al., 2002).
Despite this widely accepted hypothesis, no study already proved
the existence of novel disulfide bonds, either intra- or intermolecular.
Importantly, abnormal disulfide bonding cannot be the only cause of
SFD as two missense mutations do not lead to the introduction or loss
of a cysteine. Controversy also exists about the dimerization capacity
of the p.(Ser179Cys) TIMP3 mutant, as some show dimerization of
the mutant (Langton et al., 2005) and others not (Qi et al., 2002).
Overall, these findings underscore our current lack in understanding
the pathogenetic mechanism underlying SFD.
In 2000, Assink et al. examined a large Belgian family with typical
SFD. Although linkage was found with the 22q12.1-q13.2 region con-
taining TIMP3, no TIMP3mutation was identified (Assink et al., 2000).
Here, it was our aim to elucidate the genetic cause of SFD in this family
and two other SFD families, and functionally characterize the mutant
proteins.
2 MATERIALS AND METHODS
2.1 Editorial policies and ethical considerations
Research protocols adhered to the tenets of the Declaration of
Helsinki andwere approved by the ethical committee ofGhentUniver-
sity (B670201733128). Patients provided written informed consent
for the study.
2.2 Clinical evaluation of patients
Three seemingly unrelated families diagnosed with SFD, two Bel-
gian and one French, were investigated. A detailed ophthalmologic
examination at baseline (consultation at presentation) included
assessment of Snellen best-corrected visual acuity (BCVA) and
refraction, slit-lamp examination, Goldmann applanation tonometry,
dilated ophthalmoscopy and extensive fundus imaging using standard
color fundus photography (Topcon TRC-50EX fundus camera; Topcon
Corporation, Tokyo, Japan), confocal scanning laser ophthalmoscopy
with blue and near-infrared auto-fluorescence (BAF and NIR-AF),
near-infrared reflectance (NIR-R) and red-free (RF) imaging (cSLO;
Heidelberg Retina Angiograph HRA2; Heidelberg Engineering,
Dossenheim,Germany), and spectral domain optical coherence tomog-
raphy (SD-OCT, Heidelberg Spectralis OCT; Heidelberg Engineering,
Dossenheim, Germany). Existing clinical records were revisited and a
full medical history was obtained to provide detailed clinical data for
each patient. Patientswere investigated and questioned about age and
mode of onset and the natural course of the disease over the years.
Eighteen individuals of family 1 underwent ophthalmological exam-
ination (Figure 1a). Family 2 consists of four individuals: two siblings
and their parents (Figure1b). Family3 consists of only the indexpatient
(Figure 1c).
2.3 Mutation analysis of TIMP3
All fiveTIMP3 (RefSeqNM_000362.4) coding exons andadjacent splice
sites were amplified from genomic DNA by polymerase chain reaction
(PCR) (Supporting Information Table S1). PCR products underwent
Sanger sequencing using the BigDye R©Terminator Cycle Sequenc-
ing kit on an ABI3730xl DNA analyzer (both Applied Biosystems).
The obtained sequences were analyzed with the SeqScape software
(AppliedBiosystems). All genomic positions are based on genomebuild
GRCh37/hg19.
2.4 Haplotyping of the TIMP3 p.(Ser38Cys)mutation
The haplotype was determined based on five probands from family 1
(IV:31, IV:56, IV:59, V:30, and V:33), two siblings from family 2 (II:1
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F IGURE 1 Pedigrees of families segregating the TIMP3 c.113C>Gmutation. (a) Reduced pedigree of family 1. Only the branches for which
segregation analysis was done are shown. (b) Pedigree of family 2. For family 1 and 2, co-segregation of themutation was shownwith disease. (c)
Pedigree of family 3. For family 3, no individuals were available for segregation analysis. (d) Sequence electropherogram of the heterozygous
c.113C>G, p.(Ser38Cys) (RefSeq NM_000362.4) variant. Abbreviations used:M=mutant allele, N= normal allele
and II:2), and one proband from family 3 (II:1) (Figure 1a–c). Haplotyp-
ing was performed using 35 single nucleotide polymorphisms (SNPs),
covering a 9 Mb region surrounding the TIMP3 gene. The genotype
of each SNP was analyzed with PCR and Sanger sequencing. Primer
sequences and SNP details are listed in Supporting Information Tables
S1 and S2.
2.5 TIMP3 expression analysis
Dermal fibroblasts derived from a skin biopsy of two patients (IV:56
and IV:59) of family 1 and four age-matched control individuals were
cultured in Dulbecco's minimal essential medium (MEM) with phe-
nol red (Thermo Fisher Scientific, 41966) supplemented with 10%
fetal calf serum, 1% penicillin-streptomycin, and 1% MEM nonessen-
tial amino acids. Cells were seeded in six well plates in triplicate at
300,000 cells per well and grown for 48 hr until confluence. Total RNA
wasextractedby scraping thewells andRNAextractionwasdoneusing
the RNeasy R© mini kit (Qiagen) with on-column DNase digestion (Qia-
gen) according to manufacturer's instructions. A second DNase treat-
ment was done using the Heat&Run gDNA removal kit (ArcticZymes)
according to manufacturer's instructions. cDNA was synthesized with
the iScript cDNA synthesis kit (Bio-Rad Laboratories) using 500 ng of
mRNA, followed by reverse-transcription quantitative PCR (RT-qPCR)
using SsoAdvanced Universal SYBR Green Supermix (Bio-Rad Labora-
tories). The expression level of TIMP3 was determined using intron-
spanning primers (primerXL (Lefever et al., 2017)). Data analysis was
done using the qBase+ software (Biogazelle) with following reference
genes for normalization: HMBS, YWHAZ, and SDHA. Primer sequences
are listed in Supporting Information Table S1.
2.6 Preparation of fibroblast cells andWestern blot
analysis
Dermal fibroblast cultures of two patients (IV:56 and IV:59) and age-
matched controlswere cultured as described above. Cellswere seeded
at 300,000 cells per well in six well plates and were grown until
confluence. After 48 hr, transforming growth factor beta-1 (TGF𝛽1,
20 𝜇g⋅ml−1) was added 24 hr prior to cell lysis to stimulate TIMP3
expression. Cell lysates were collected by scraping the cells in Laemmli
lysis buffer or M-PER mammalian protein extraction reagent (Thermo
Scientific) complemented with complete protease inhibitor cocktail
(Sigma-Aldrich) and phosphatase inhibitors (Sigma-Aldrich). Protein
concentrations were measured using the Pierce BCA protein assay
kit (Thermo Scientific). Equal amounts (30 𝜇g) of protein sample were
reduced by incubation at 98◦C with 1 M DTT and subjected to SDS-
PAGE using NuPAGETM 4–12% Bis-Tris protein gels (Invitrogen, Life
Technologies). Subsequently, proteins were transferred to a nitrocel-
lulosemembrane using the iBlot R©2 System (Life Technologies).
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In general, Western blots were first optimized using two different
membrane blocking buffers (2%membrane blocking agent (GEHealth-
care Life Sciences)) in 1x Tris-buffered saline with Tween-20 (TBST)
or 2% BSA in TBST and different antibody concentrations, ranging
between 1:500 and 1:2000.
Membraneswere incubated inblockingbuffer (TBST, 2%membrane
blocking agent (GEHealthcare Life Sciences)) for 2hr at roomtempera-
ture and immunolabeledwith primary antibody (T7687, Sigma-Aldrich
or MAB3318, Calbiochem) diluted 1:1000 in blocking buffer for 16 hr
at 4◦C.Membranes were probed with secondary antibody (anti-rabbit
IgG and anti-mouse IgG,HRP-linked antibody (Cell Signaling Technolo-
gies)) diluted 1:2500 in blocking buffer for 2 hr at room tempera-
ture. Membranes were developed using the SuperSignal R©West Dura
ExtendedDuration Substrate kit (Thermo Scientific, Life Technologies)
and scannedwith the ChemiDoc-It R© 500 Imaging System (UVP).
In blots with M-PER cell lysates, relative densities of glycosylated
TIMP3 were calculated on three independent Western blots using
Image J. Relative ratios of glycosylated TIMP3 were calculated to
the total amount of TIMP3 present in the sample. Statistical anal-
ysis was done using an unpaired t-test. Furthermore, 𝛽-tubulin was
used as internal loading control. For this, membranes were stripped
using the Restore PLUSWestern Blot Stripping Buffer (Life Technolo-
gies) and probed with 𝛽-tubulin primary antibody (ab6046, Abcam)
diluted 1:2000 in blocking buffer for 1 hr at room temperature and
subsequently probed with secondary antibody (anti-rabbit IgG, HRP-
linked antibody (Cell Signaling Technologies)) diluted 1:2500 in block-
ing buffer for 1 hr at room temperature. Developing was done as
described above.
ECM extracts were made by removing dermal fibroblasts from the
well by trypsinization, subsequent washing with phosphate buffered
saline (PBS) and scraping of the remaining proteins in ECMbuffer con-
taining 100 mM Tris-HCl [pH 6.8], 10% glycerin, and 1% SDS (Weber
et al., 2002). SDS-PAGE and protein transfer to nitrocellulose mem-
brane was performed as described above. Membranes were blocked
for 2 hr and immunolabeled with primary antibody (AB6000, Merck
Millipore, 1:2000 or MAB3318, Calbiochem, 1:1000), respectively
diluted in 2% BSA or 2% membrane blocking agent in TBST for 16 hr
at 4◦C. Membranes were probed with secondary antibody and devel-
oped as described above.
2.7 In vitro transcription and translation of TIMP3
protein and subsequentWestern blot analysis
We constructed wild type (WT) and mutant (c.113C>G, p.(Ser38Cys)
and c.536C>G, p.(Ser179Cys)) expression constructs starting from the
Gateway pcDNA-DEST47 vector (Invitrogen, Life Technologies) and
a WT or mutant TIMP3 open reading frame (ORF) containing vec-
tor (Integrated DNA Technologies) using a combined Gateway BP-
LR-recombination reaction (Invitrogen, Life Technologies). Plasmids
were transformed inOne Shot TOP10 competent cells (Invitrogen, Life
Technologies) and subsequently isolated with the NucleoBond Xtra
Midi/Maxi kit (Macherey-Nagel). The entire TIMP3 inserts and the
surrounding backbone were Sanger sequenced and selected plasmids
were grown to obtain larger quantities.
In vitro transcription and translation of generated WT and mutant
expression constructs was done using the T7 TnT R© Quick Coupled
Transcription/Translation System (Promega) according to manufac-
turer's instructions. Briefly, 1𝜇gof expression constructwas incubated
for 75 min at 30◦C together with 40 𝜇l of TNT Quick Master mix, 1 𝜇l
Methionine, and 1 𝜇l PCR enhancer. Generated proteins were treated
with Rnase A (0.2 𝜇g⋅𝜇l−1) for 5 min at 30◦C. Protein concentration
was determined using the Pierce BCA protein assay kit (Thermo Sci-
entific) and equal amounts of protein (30 𝜇g) were subjected to SDS-
PAGE onNuPAGETM 4–12%Bis-Tris ProteinGels orNovexTM 10–20%
Tris-Glycine protein gels (Invitrogen, Life Technologies). Anti-TIMP3
antibodies (AB6000, Merck Millipore, 1:2000 or MAB3318, Cal-
biochem, 1:1000) were used as described earlier.
2.8 Molecular modeling of TIMP3–MMP2
interaction
A homology model for full-length TIMP3 was generated using the
homology modeling command in YASARA structure (version 17.8.15)
using the structure of TIMP2 (PDB code: 1GXD, chain D) as a tem-
plate (http://yasara.org/products.htm#structure). Homology modeling
used a MAFFT alignment (Supporting Information Figure S1A) guided
by structural alignment of TIMP2 (1GXD) and the TIMP3 N-terminal
domain (3CKI) (Katoh & Standley, 2013). A model for the complex
of full-length TIMP3 with pro-MMP2 was generated as above, but
now using TIMP2 and pro-MMP2 as templates, as present in the
1GXD template structure (chain A and C). A model of TIMP3 with
MMP2 was generated by superposing the structure of the MMP2
protease domain (PDB code: 1QIB) on the TACE protease domain
in the TIMP3/TACE crystal structure (PDB code: 3CKI) using UCSF
chimera matchmaker, superposing only a selection of residues around
the metal binding site (Supporting Information Figure S1B) (Pettersen
et al., 2004). After removal of the TACE structure, residues 100–
121 of TIMP3 were replaced by residues of the full-length TIMP3
homology model using YASARA structure, generating a model of full-
length TIMP3withMMP2. Themodel was energy minimized using the
YASARA em_runcleanmacro.
The effect ofmutations on protein structurewas analyzed using the
YASARA structure md_refine protocol, which combines 500 ps molec-
ular dynamics, with energyminimization of frames taken at 25 ps inter-
vals. The mutation was tested in the crystal structure of the TIMP3
N-terminal domain (PDB code: 3CKI, without TACE) and in the homol-
ogy model of full-length TIMP3. Both WT and mutant were subjected
to five different md_refine runs. The energyminimized structures with
lowest energy of each simulation, and the structures after 400, 425,
450, 475, and 500 ps simulation were all compared after different
structural superpositions inUCSF chimera andYASARA. Visual inspec-
tion of the superpositions revealed no reproducible visible differences
between theWT andmutant models.
2.9 Prediction of the effect of the p.(Ser38Cys)
mutation on protein stability
The effect of the p.(Ser38Cys) mutation on the protein stability
was tested using FoldX (Guerois, Nielsen, & Serrano, 2002), DUET
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(Pires, Ascher, & Blundell, 2014), and MAESTRO (Laimer, Hofer, Fritz,
Wegenkittl, & Lackner, 2015). FoldX calculations used the FoldX Build-
Model protocol after RepairPDB preparation of the structure or
model. DUET calculations used the DUET webserver (http://biosig.
unimelb.edu.au/duet/stability), and generated DUET,MCSm, and DSM
stability scores. MAESTRO calculations used the MAESTROweb web-
server (https://biwww.che.sbg.ac.at/maestro/web).
2.10 Generation ofmutant (p.(Cys36Ser) and
p.(Cys143Ser)) constructs and in vitro transcription and
translation
The c.107G>C, p.(Cys36Ser) and c.428G>C, p.(Cys143Ser) mutations
were inserted into WT or mutant (c.113C>G, p.(Ser38Cys)) TIMP3
expression constructs, used to predict the effect of the p.(Ser38Cys)
mutation on disulfide bond formation. The mutations were inserted
using the Q5 site-directedmutagenesis kit (New England Biolabs), and
mutation-specific primers were designed with the NEBaseChanger
software (New England Biolabs) (Supporting Information Table S1).
Mutated plasmids were transformed in One Shot TOP10 competent
cells (Invitrogen, Life Technologies) and subsequently isolatedwith the
NucleoBond Xtra Midi/Maxi kit (Macherey-Nagel). The entire TIMP3
insert was sequenced and selected plasmids were grown to obtain
larger quantities. Sequencingprimers canbe found in Supporting Infor-
mationTable S1. In vitro transcription and translationwas performedas
described above.
3 RESULTS
3.1 Clinical evaluation of three SFD families
Supporting Information Table S3 summarizes the phenotypic data
for the three families. Only one third of the patients explicitly com-
plained about night blindness in their fifth decade. The other patients
did not, although the majority of them were older than 50 years. In
one patient photophobia was more important early on in the disease
course.
When examined in the third decade, the fundus appearance was
considered to be normal or near-normal with only few small white
deposits with limited RPE alterations. Patients in their fourth decade
often showed fine drusen located in the mid-periphery beyond the
temporal vascular arcades without obvious or important macular
changes. This evolved toward a 360◦ spread of numerous drusen in the
mid-periphery in the fifth decade with both RPE pigmentary changes
in the far periphery and earlymacular changes. Further on, CNVdevel-
ops together with fibrosis and RPE hyperplasia and atrophy not only
confined to the posterior pole but also present in the (mid-) periphery.
All patients kept an optimal best-corrected visual acuity in at least one
eye until the sixth decade (with the exemption of one patient). Patients
in the seventh decade or older had rapidly evolved toward legal blind-
ness due to macular scarring and/or atrophy. However, in these older
patients CNVs commenced unfortunately in a pre-anti-VEGF era and
therefore rapid scarring was unavoidable (Figure 2). Two patients con-
tinue to undergo regular intravitreal injections with anti-VEGF (off-
label bevacizumab). In one patient, this was advised despite BCVA loss
andmacular scarring in order to reduce peripheral CNV activity and to
preserve peripheral visual function.
None of our patients had pulmonary involvement. Although, cur-
rently, no further investigations were performed to detect asymp-
tomatic air trapping in the absence of clinical signs, symptoms, or
complaints.
3.2 Identification of a p.(Ser38Cys) mutation in the
TIMP3 gene in three SFD families
We performed Sanger sequencing of all five coding exons and sur-
rounding exon-intron borders of TIMP3. This revealed a mutation in
the first exonof family1: c.113C>G,p.(Ser38Cys) (NM_000362.4) (Fig-
ure 1d). This is a known pathogenic variant in the TIMP3 gene and one
of only two mutations currently identified in the N-terminal region of
theprotein (Meunier et al., 2016; Schoenberger&Agarwal, 2013;War-
wick, Gibson, Sood, & Lotery, 2015) (Figure 3). Segregation analysis in
60 family members showed co-segregation with disease in 47 individ-
uals of family 1 (Figure 1a). In addition, the mutation was identified
in 13 individuals who, as far as we know, do not present with a SFD
phenotype yet and are indicated with a black dot on the pedigree (Fig-
ure 1a). Subsequently, the same N-terminal mutation was identified in
two additional SFD families, family 2 and 3 (Figure 1b,c). The mutation
segregated with disease in four individuals of family 2.
3.3 The p.(Ser38Cys)mutation is a foundermutation
Two of the SFD families in which the p.(Ser38Cys) mutation segre-
gates are of Belgian descent (family 1 and 3) and one is French (fam-
ily 2). Haplotype reconstruction for all three families was done, as we
assumed a common origin of this mutation. We genotyped 35 SNPs,
covering a 9 Mb region surrounding the TIMP3 gene, in five patients
(IV:31, IV:56, IV:59, V:30, andV:33) of family 1, two patients of family 2
(II:1 and II:2), and the proband (I:1) of family 3. Interestingly, all individ-
uals harbored the same haplotype up to a distance of 5.6Mb upstream
and 737 kb downstream of TIMP3 (Figure 4). Overall, this showed a
shared region of about 6.4Mb, suggesting that thismutation originates
from an ancient common ancestor.
3.4 The p.(Ser38Cys) mutation does not alter TIMP3
mRNA expression
To exclude whether the p.(Ser38Cys) mutation affects TIMP3 mRNA
expression, RT-qPCR expression analysis was performed on total RNA
extracted from fibroblast samples. No difference in TIMP3 expres-
sion levels was observed between two affected individuals of family 1
(IV:56 and IV:59) and four age-matched control individuals (unpaired
t-test, p-value= 0.2) (data not shown).
3.5 The p.(Ser38Cys) mutation does not lead to the
formation of higher-molecular weight proteins
To study the effect of the identified mutation on protein level, we per-
formedextensiveWestern blot analyses onwhole cell lysates andECM
extracts of patient and control fibroblasts using two different lysis
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F IGURE 2 Composite of clinical images. (a) Posterior pole of right eye of a 51-year-old male patient withminimal drusen, more pronounced
around the superior avascular arcades (ellipse). (b,c) Composite of posterior pole andmid-periphery of right eye of female patient at ages 65 and
72 years, respectively, illustrating evolution of phenotype over timewith drusen inmacula and around vascular arcades as well as patchy outer
retinal atrophy (b), evolving to widespread chorioretinal atrophy, macular atrophy and subretinal neovascularization, and exudation and
hyperpigmentation over a period of 7 years (c). (d) Left eye of a 74-year old female patient showing complete outer retinal atrophy, extreme
hyperpigmentation, exudation consequent upon subretinal neovascularization, and fibrosis
F IGURE 3 TIMP3 protein structure and SFD causingmutations. Cysteine residues are indicatedwith black boxes and corresponding disulfide
bridges with connecting black lines (UniProtKB P35625). Knownmutations are indicated beneath the figure (RefSeq NM_000362.4, NP_000353).
Themutation studied here is indicated in bold. The N- and C- terminal domains are separated by a dashed line (Bakall et al., 2014; Barbazetto,
Hayashi, Klais, Yannuzzi, & Allikmets, 2005; Felbor et al., 1996; Felbor, Stohr, Amann, Schonherr, &Weber, 1995; Felbor, Suvanto, Forsius,
Eriksson, &Weber, 1997; Fung, Stöhr,Weber, Holz, & Yannuzzi, 2013; Gliem et al., 2015; Jacobson et al., 1995, 2002; Langton et al., 2000; Lin
et al., 2006; Saihan et al., 2009; Schoenberger & Agarwal, 2013; Tabata, Isashiki, Kamimura, Nakao, &Ohba, 1998;Weber et al., 1994)
buffers, both reducing and nonreducing conditions, and three different
anti-TIMP3 antibodies, each recognizing a different epitope. TIMP3
and its glycosylated form have a respective molecular weight of 25
and 27 kDa and can be seen on all blots using patient fibroblasts
(Figure 5a–f). We confirmed TIMP3 localization to the ECM,
as ECM extracts show a clear enrichment in TIMP3 protein
(Figure 5e,f).
Western blot analysis was performed on whole cell lysate using
Laemmli lysis buffer and two different antibodies (Calbiochem,
Sigma) (Figure 5a,b). Statements about higher-molecular weight forms
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F IGURE 4 Haplotype reconstruction. SNPs covering a 9Mb region around the TIMP3 gene revealed a shared haplotype of maximal 6.47Mb.
Only a selection of relevant markers is shown. For full marker data, see Supporting Information Table S2
F IGURE 5 Overview of TIMP3Western blot experiments. (a–d)Western blot analysis on whole cell lysates of patient and control fibroblasts
using two lysis buffers (a,b: Laemmli; c,d; M-PER) and two primary TIMP3 antibodies (a,c: Calbiochem; b,d: Sigma). (e,f)Western blot analysis on
ECMextracts of patient and control fibroblasts using two primary TIMP3 antibodies (e: Calbiochem; f: Merck). (g,h)Western blot analysis on in
vitro transcription and translation products of wild type andmutant TIMP3 constructs using two primary TIMP3 antibodies (g: Calbiochem; h:
Merck). TIMP3 and glycosylated TIMP3 have a respectivemolecular weight of 25 and 27 kDa. Previous hypotheses about higher-molecular
weight proteins could not be confirmed, however mild hyperglycosylation was observed in patients versus controls when usingM-PER lysis buffer
(c,d). Abbreviations used: P= patient, C= control, ECM= extracellular matrix, TGF𝛽 = transforming growth factor beta, wt=wild type TIMP3, N
term= TIMP3with N terminal mutation p.(Ser38Cys), C term= TIMP3with C terminal mutation p.Ser179Cys, NT= no template control
occurring only in patients could not be made as nonspecific bands,
observed in both patients and controls,mask the region around50 kDa
where TIMP3 dimers are expected (Arris et al., 2003; Langton et al.,
1998; Langton et al., 2005; Langton et al., 2000; Saihan et al., 2009;
Soboleva et al., 2003; Weber et al., 2002; Yeow et al., 2002). Impor-
tantly, this band does not disappear when samples are reduced with
1 M 1,4-dithiothreitol (DTT), which is more suggestive of nonspecific
binding of both antibodies rather than TIMP3 dimerization (Fig-
ure 5a,b). As TIMP3 is known to localize to the ECM (Li et al.,
2005), ECM extracts were collected of patient and control fibroblasts.
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Western blot analysis on these extracts was performed, using the
same antibody as in Figure 5a (Calbiochem) (Figure 5e). We can-
not explain the increased intensity of glycosylated TIMP3 in P1,
which was not present anymore when repeating the experiment
on new ECM extracts using a third antibody (Merck) (Figure 5f).
More interestingly, the nonspecific band at 50 kDa seen in Fig-
ure 5a,b was not present in the ECM extracts using two dif-
ferent antibodies (Calbiochem, Merck) (Figure 5e,f). This observa-
tion is an additional argument for nonspecific binding of the pri-
mary antibody to proteins present in the whole cell lysate, but
not present in the ECM extracts. Furthermore, we do not observe
TIMP3 dimers/multimers present in patient ECM extracts. Based on
these observations, we cannot confirm the hypothesis on TIMP3
dimerization proposed by Arris et al. and others for distinct TIMP3
mutations, using the same antibody (Sigma) and fibroblast extracts
(Arris et al., 2003;Weber et al., 2002).
Next, cell lysis was performed with M-PER mammalian protein
extraction reagent (Thermo Fisher Scientific), which provides a milder
cell lysis than Laemmli lysis buffer and keeps the proteins in their
native state (Figure 5c,d). Interestingly, subsequentWestern blot anal-
ysis revealed a (minor) increase in glycosylated TIMP3 in reduced
patient versus control samples and this effect was even increased
upon stimulation of TIMP3 expression using TGF𝛽1 (Su, DiBattista,
Sun, Li, & Zafarullah, 1998) (Figure 5c,d). This effect was quantified on
three independent Western blots using densitometry for one patient
and one control sample with endogenous (-TGF𝛽) protein expression,
and relative densities of glycosylated TIMP3 to the total amount
of TIMP3 were calculated. Patient samples show a statistically
significant increase in glycosylation compared to control samples
(p= 0.0016) (Supporting Information Figure S2).
Finally, we performed nonreducing Western blot analysis on WT
and the following mutant TIMP3 proteins, all created by in vitro tran-
scription and translation of TIMP3 expression vectors: p.(Ser38Cys)
(N-terminal domain) and p.(Ser179Cys) (C-terminal domain). Again, no
differences were observed between unglycosylated WT and mutated
forms of TIMP3. All other bands are aspecific as they also occur in the
negative control sample, where no plasmid was added to the in vitro
transcription and translation reaction (Figure 5g,h).
Overall, based on all antibodies that were tested in this study, we
prefer the AB6000 antibody (Merck Millipore) to analyze TIMP3 pro-
teins, as this is the most sensitive for TIMP3 and shows the least non-
specific binding.
3.6 Structural modeling of TIMP3—(pro-)MMP2
interaction
The crystal structure of the N-terminal domain of TIMP3 has been
determined in complexwith theTACEcatalytic domain (PDBcodeCKI)
(Wisniewska et al., 2008). We further built molecular models of the
complete TIMP3, and of complete TIMP3 with MMP2 (Figure 6a) or
pro-MMP2 (Figure 6b). Using this crystal structure and the complete
TIMP3 homology model, we predicted the effect of the p.(Ser38Cys)
mutation on protein stability using the structure-based predictors
FoldX,DUET, SDM,mCSM, andMAESTRO(Guerois et al., 2002; Laimer
F IGURE 6 Models of TIMP3 bound toMMP2 or pro-MMP2. (a)
TIMP3 is colored gray, residues 1–37 are colored blue. MMP2 is
colored pink. Disulfides are displayed, and the position of Ser38 and
theMMP2 active site are indicated. (b) The N-terminal domain of
TIMP3 is colored gray, the C-terminal domain is colored blue.
Pro-MMP2 is colored pink. Disulfides are displayed, and the position
of Ser38 and Cys36 is indicated. Ser38 is not close to the interface
withMMP2 or pro-MMP2, and the p.(Ser38Cys) mutation does not
strongly affect stability or structure of the TIMP3 protein.
Interestingly, Ser38 is close to Cys36, which forms a disulfide bridge
with Cys143 in wild type TIMP3
et al., 2015; Pires et al., 2014). Prediction results did not agree well
and suggested that the mutation is either moderately stabilizing, neu-
tral, or at best moderately destabilizing, with a maximum destabilizing
ΔΔG of -0.84 kcal⋅mol−1 (Supporting Information Table S4), which is
in concordance with the Western blot results showing no difference
in protein expression between wild type and mutant forms of TIMP3.
In the crystal structure and homology models, Ser38 is not close to
the TIMP3 interface with TACE,MMP2 (Figure 6a) or pro-MMP2 (Fig-
ure 6b). However, a p.(Ser38Cys) mutation could affect the binding by
long-range structural effects.We further mutated Ser38 to cysteine in
the structure and homologymodel, followed by analyses of themutant
and WT protein using the Yasara md_refine protocol (Krieger et al.,
2009). This protocol combines short molecular dynamics and energy
minimization with the YASARA2 forcefield, and on average improves
protein structuremodels (Krieger et al., 2009). This approach does not
indicate any remarkable effect of the p.(Ser38Cys) mutation on the
protein structure. Together, stability prediction and modeling do not
provide convincing indications that a p.(Ser38Cys) mutation strongly
affects stability or structure of the TIMP3 protein.
However, these approaches cannot predict the consequences of
the introduction of the new cysteine on misfolding due to faulty new
disulfide bridges during the folding process. For example, Ser38 is in
close proximity to Cys36, which forms a disulfide bridge with Cys143
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(Figure 6b). A cysteine at position 38 may compete with this correct
disulfide bridge formation and interact with Cys36 to form a novel,
aberrant disulfide bond.
3.7 The p.(Ser38Cys) mutation possibly disrupts an
intramolecular disulfide bond
As we hypothesize that the Cys36-Cys143 disulfide bond may be
disrupted by the introduction of the p.(Ser38Cys) mutation, we per-
formed Western blot analysis with WT and mutant p.(Ser38Cys) and
p.(Ser179Cys) TIMP3 proteins generated by in vitro transcription and
translation.Disturbanceof theCys36-Cys143bond, covalently tether-
ing theC-terminal andN-terminal domain, and aberrant disulfide bond
formation with the cysteine at position 38, is expected to give rise to a
(moderate) change in apparent molecular weight. To be able to detect
small differences in molecular weight, protein gels were used with
an increased separation capacity between 20 and 30 kDa. Six inde-
pendent high-resolution Western blots using nonreducing conditions
showed an increase in apparent molecular weight for the protein con-
taining the N-terminal p.(Ser38Cys) mutation compared toWT TIMP3
and the C-terminal p.(Ser179Cys) mutation. Moreover, this shift in
molecularweight disappearswhen reducing the sampleswith 1MDTT,
which further supports aberrant disulfide bond formation (Supporting
Information Figure S3).
To confirm this hypothesis, additional TIMP3 constructs contain-
ing a p.(Cys36Ser) or p.(Cys143Ser) mutation, disrupting the wild type
Cys36-Cys143 disulfide bond, were generated in combination with
the WT or mutant p.(Ser38Cys) construct (Figure 7). Interestingly,
we could detect a similar upward shift in apparent molecular weight
on five independent nonreduced Western blots between the mutant
p.(Ser38Cys) construct (Figure 7a, lane 2) and the construct containing
both the p.(Ser38Cys) and p.(Cys143Ser) mutations, suggesting that
the shift of the Ser38Cys mutant is not caused by a de novo Cys38-
Cys143 disulfide bond (Figure 7a, lane 7). In contrast, the upward shift
of the p.(Ser38Cys) mutation was abolished when using a plasmid that
combines a p.(Ser38Cys) and p.(Cys36Ser) mutation, suggesting that
the upward shift requires Cys36 (Figure 7a, lane 6). Overall these data
suggest that Cys38 may indeed form an aberrant disulfide bridge with
Cys36 (Figure 7c). The combination of WT TIMP3 and the mutant
p.(Ser38Cys) construct (Figure 7a, lane 3), mimicking a heterozygous
situation as observed in the patients, results in a broad band with a
size overlappingwith both theWTconstruct and the p.(Ser38Cys) con-
struct, suggesting that both protein forms are represented.
4 DISCUSSION
We have identified the causal mutation of SFD in three different fam-
ilies from Belgian or French origin. All affected individuals are het-
erozygous for the c.113C>G, p.(Ser38Cys) mutation in exon 1 of the
TIMP3 gene, which was previously missed in family 1 due to less sen-
sitive screening methods (Figure 1). This mutation has been associ-
ated with relatively late onset SFD leading to choroidal neovascular-
ization, with or without pulmonary involvement (Meunier et al., 2016;
Schoenberger & Agarwal, 2013; Warwick et al., 2015). We confirm a
later onset in the families identified here, segregating the p.(Ser38Cys)
mutation. Themajority of patients remained completely asymptomatic
way into their fifth decade, with optimal visual function in almost all
individuals until the sixth decade. Older individuals often had lost their
eyesight due to complicated CNV's in the absence of treatment with
anti-VEGF (Figure 2, Supporting Information Table S3). A strict follow-
up, including self-monitoring, is advised to all younger patients in order
to start anti-VEGF treatment at the earliest sign of CNV develop-
ment. Macular atrophy is an important part of the Sorsby clinical spec-
trum.With the later onset of visual problems in our families compared
to typical SFD, the phenotype could be mistaken for AMD. However,
(mid-)peripheral changes occur at an earlier age compared to AMD
and know a more rapid spread and progression. Despite the clinical
heterogeneity, we found evidence of genetic homogeneity. Haplotype
reconstruction of 35 genetic markers revealed a common haplotype of
maximal 6.47Mb, which points to a founder mutation originating from
an ancient ancestor in theWestern-European population (Figure 4).
To date, 18 different TIMP3mutations have been identified to cause
SFD (Figure 3). The mechanisms underlying TIMP3-associated SFD
remain largely unidentified. The p.(Ser38Cys) mutation is one of the
two located in the N-terminal region of TIMP3, which functions in
MMP inhibition. Asmost TIMP3mutations, p.(Ser38Cys) adds an addi-
tional cysteine to the protein, inwhich12 conserved cysteinesmakeup
six disulfide bridges that are crucial for folding and structural stability
of the protein. These bridges are essential for proteins destined for the
secretory pathway, such as TIMP3, as they are exposed to highly oxi-
dizing environments (Bechtel & Weerapana, 2017; Ellgaard, McCaul,
Chatsisvili, & Braakman, 2016).
So far, it is unclear how the disease develops and a mechanism
explaining the pathogenicity of TIMP3 mutations is currently lacking.
A first hypothesis suggests a gain of function whereby mutant TIMP3
proteins containing an unpaired cysteine form abnormal disulfide-
bonded dimers and aggregates that slow down turnover in the Bruch
membrane (Langton et al., 2000). Dimerization/multimerization of the
mutant protein has been shown for different C-terminal mutations
(Arris et al., 2003; Christensen et al., 2017; Langton et al., 1998; Lang-
ton et al., 2005; Saihan et al., 2009; Soboleva et al., 2003;Weber et al.,
2002; Yeow et al., 2002) (Supporting Information Table S5). However,
some discrepancies remain on the ability of mutant proteins to dimer-
ize/oligomerize, depending on the cell line or expression construct
used (Langton et al., 2005). Furthermore, this hypothesis is less likely
for mutations that do not lead to the gain or loss of a cysteine (Lin
et al., 2006; Saihan et al., 2009). A second hypothesis involves reduced
capacity of mutant TIMP3 to inhibit MMP activity or VEGF signaling.
Again contradictory results exist, where a retained MMP inhibitory
function was shown for the majority but not all of TIMP3 mutations
evaluated (Christensen et al., 2017; Langton et al., 2005; Langton et al.,
2000; Qi et al., 2002; Yeow et al., 2002)) (Supporting Information
Table S5).
No functional data concerning the p.(Ser38Cys) mutation are cur-
rently available. As this mutation gives rise to an unpaired cysteine,
we performed extensive Western blot analyses on different sample
types and using different antibodies to assess the presence of TIMP3
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F IGURE 7 Nonreduced TIMP3Western blot using in vitro transcription and translation proteins. (a)Western blot of wild type or mutant TIMP3
constructs containing (combinations of) themutation of interest and p.(Cys36Ser) or p.(Cys143Ser), which disrupt the wild type Cys36-Cys143
disulfide bond. (b) The p.(Ser38Cys) mutation disturbs an intramolecular disulfide bond, which can be seen as an increase inmolecular weight (a,
lane 2). (C) Combination of the p.(Ser38Cys) and p.(Cys143Ser) mutation disturbs formation of the Cys36-Cys143 disulfide bond and induces
Cys36-Cys38 disulfide bond formation (a, lane 7), which leads to the same shift in molecular weight as observed for p.(Ser38Cys) alone (a, lane 2)
dimers (Figure 5). We could, however, not identify protein aggregates
in any experiment. Two antibodies (T7687, Sigma and MAB3318, Cal-
biochem) detected a strong immunoreactive band at 50 kDa in whole
cell lysates (but not ECM), which did not disappear following 1 M DTT
reduction. Furthermore, this band was also present in the no template
control of an in vitro transcription and translation reaction, which sug-
gests that these are nonspecific bands arising from proteins present in
whole cell lysates. A third antibody (Merck) confirmed the absence of
TIMP3 dimers/multimers in patient ECM extracts and in vitro derived
mutant protein. Overall, our findings do not support TIMP3 dimeriza-
tion for the p.(Ser38Cys) mutation.
Molecular modeling of the mutant TIMP3 protein together with
two of its interaction partners, MMP2 and pro-MMP2, did not sug-
gest a direct effect of the p.(Ser38Cys) mutation on protein stabil-
ity, or reveal a disturbance in interaction pattern as the mutation is
not close to the interaction interfaces with MMP2 or pro-MMP2 (Fig-
ure 6). However, these predictions do not take into account alter-
ations of the disulfide bridge pattern. In wild type TIMP3, Cys36 forms
a disulfide bond with Cys143, covalently tethering the N-terminal
and C-terminal domain of the protein. As p.(Ser38Cys) is in close
proximity to Cys36 (Figure 6), we hypothesized a disruption of the
Cys36-Cys143 disulfide bond and potential formation of a novel one.
This hypothesis was subsequently confirmed by high-resolutionWest-
ern blot analysis of p.(Ser38Cys) mutant protein compared to wild
type or p.(Ser179Cys) mutant protein (Supporting Information Fig-
ure S3), showing an upward shift in apparent molecular weight of the
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p.(Ser38Cys) mutant TIMP3 compared to wild type or p.(Ser179Cys)
mutant protein. The shift disappears when reducing the samples with
1 M DTT, which disrupt disulfide bonds, thus confirming that the
identified shift indeed arose from abnormal disulfide bonding. Fur-
ther experiments with combined mutants of the Cys36, Ser38, and
Cys143 residues suggested formation of a de novoCys36-Cys38 disul-
fide bridge (Figure 7). Several instances of disulfide bridged Cys-X-Cys
motifs are present in the PDB structure database. Importantly, this
change in intramolecular rather than intermolecular disulfide bond-
ing due to a free cysteine might explain the absence of TIMP3 protein
dimers for the p.(Ser38Cys) mutation.
The aberrant, novel Cys36-Cys38 disulfide bond is expected to
affect the tertiary structure of both the N-and C-terminal domains.
The disruption of the Cys36-Cys143 disulfide bridge makes the N-
and C-terminal domain of the protein less tethered, which may even
mean that the p.(Ser38cys)mutation in theN-terminal domain de facto
affects the function of theC-terminal domain. This is interesting, as it is
striking that the vast majority of TIMP3 mutations in SFD occur in the
C-terminal domain (Figure 3). The C-terminal domain ascertains the
interaction with the ECM, inhibits activation of pro-MMPs and bind-
ing of VEGF to VEGFR2 (Brew & Nagase, 2010; Nagase et al., 2006;
Qi&Anand-Apte, 2015), and interactswithEFEMP1 (Klenotic,Munier,
Marmorstein, & Anand-Apte, 2004).
Interestingly, the TIMP3 C-terminal domain contains a single N-
glycosylation site at Asn207, which is part of the pro-MMP2 binding
site. For other TIMPs, it has already been suggested that an early, intra-
cellular interaction between TIMPs and pro-MMPs can affect protein
maturation such as glycosylation (Roderfeld et al., 2007). It is there-
fore possible that the faulty disulfide bonding alters thebinding affinity
of TIMP3 to its C-terminal binding partners such as pro-MMPs, which
could influence glycosylation of the TIMP3 protein. In this respect,
we detected a moderate increase in TIMP3 glycosylation in whole cell
lysate from one patient compared to a control (Figure 5c,d). However,
obtaining access to additional patient samples would be of interest to
further support this finding.
This observation is reminiscent to the findings of Qi et al., who
identified a similar difference in glycosylation status for the SFD
p.(Ser179Cys) C-terminal mutation. Possible consequences of exces-
sive glycosylation are reduced binding to the ECM by masking basic
residues in the protein and a reduced MMP inhibitory function due to
a conformational change (Qi et al., 2009).
Importantly, the exact effect of the altered intramolecular bond-
ing caused by p.(Ser38Cys) on the glycosylation status and function
of TIMP3, such as binding/inhibition of (pro-) MMPs, VEGFR2, or
EFEMP1, is currently unknown. Both gain of function and loss of func-
tion are possible. In a gain of function model, the aberrantly folded
mutant protein is less prone to degradation than the wild type protein
and leads to accumulation of TIMP3 in the Bruch membrane. Eventu-
ally this would lead to disruption of the RPE, as seen in SFD patients.
In a loss of function model, the mutant protein has a reduced abil-
ity to inhibit MMPs or VEGF, which would lead to ECM dysregulation
and CNV (Christensen et al., 2017). Further research is necessary to
determinewhichmodel is applicable for thep.(Ser38Cys)mutation and
if all SFD-variants have a shared diseasemechanism.
In the current study patient-derived fibroblasts were used, simi-
lar to previous papers (Arris et al., 2003; Weber et al., 2002). How-
ever, given the major involvement of the RPE, other cell types such as
induced pluripotent stem cell (iPSC)—derived RPE from patients with
SFD would be of interest in assessing the downstream effect of the
altered intramolecular disulfide bonding and how thismutation affects
the RPE. This cell type already showed great potency in mimicking
adult human RPE and it has been shown that iPSC-RPE from patients
with SFD exhibits drusen and ECM alterations (Galloway et al., 2017).
In conclusion, we identified a heterozygous TIMP3 founder muta-
tion (c.113C>G, p.(Ser38Cys)) in three families with late-onset SFD.
We were not able to confirm the general hypothesis on abnormal
intermolecular disulfide bonding resulting in aberrant TIMP3 pro-
tein dimerization. Instead, we propose a novel pathogenetic mecha-
nism for this N-terminal mutation comprising the formation of a novel
intramolecular disulfide bond with a potential effect on TIMP3 glyco-
sylation.
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